Peer-reviewed veterinary case report
Long-term safety and effects of bezafibrate for dogs with high
By Castonguay-Poirier, Marilou et al.·Published in Journal of veterinary internal medicine·2026·Internal Medicine Department, Canada·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Long-term safety and efficacy of oral bezafibrate use in dogs with hypertriglyceridemia.
- Species:
- dog
Plain-English summary
A group of 55 dogs with high triglyceride levels (hypertriglyceridemia) were treated with a medication called bezafibrate. Over time, most dogs showed a significant decrease in their triglyceride levels, with an average reduction of 85%. While some dogs experienced mild gastrointestinal or liver issues, the overall long-term use of bezafibrate was found to be safe and effective for managing this condition. If your dog has high triglycerides, bezafibrate might be a treatment option worth discussing with your veterinarian.
People also search for: dog high triglycerides treatment · bezafibrate for dogs · dog liver problems from medication
Abstract
BACKGROUND: Bezafibrate (BZF) is effective for the treatment of hypertriglyceridemia in dogs, but there is limited data on its long-term use. HYPOTHESIS/OBJECTIVES: Assess the long-term safety and efficacy of BZF in controlling primary and secondary hypertriglyceridemia in dogs. ANIMALS: Fifty-five client-owned dogs with hypertriglyceridemia. METHODS: Retrospective study. Dogs were treated with BZF once daily at a median initial dosage of 5.5 mg/kg (range, 3.6-11.6 mg/kg) and classified into 3 groups: primary hypertriglyceridemia (group 1), secondary hypertriglyceridemia without changes in treatment for the underlying condition over time (group 2a) or with changes in treatment for the underlying condition over time (group 2b). Serum triglyceride (TG) concentration, and creatine kinase (CK) and alanine aminotransferase (ALT) activities were recorded before treatment (T0) and at subsequent follow-ups (1, 3, 6, 12, and >18 months, as available). Treatment response was classified as adequate (TG decreased by ≥50 % T0) or inadequate (TG decreased by <50% T0). RESULTS: All groups showed a significant decrease in TG concentration between baseline (T0) and the last available result (P <.01). No significant differences in the last follow-up TG concentration were observed among the 3 groups (P = .13). The median TG decrease across all groups during the study period was 85%. Adverse gastrointestinal or hepatic effects, possibly attributable to BZF, were observed in 4/55 dogs. CONCLUSIONS AND CLINICAL IMPORTANCE: Long-term use of BZF proved safe and effective for most dogs with primary and secondary hypertriglyceridemia.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41818730/